Benson L A, Healy B C, Gorman M P, Baruch N F, Gholipour T, Musallam A, Chitnis T
Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, MA, USA; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, 1 Brookline Place, Boston, MA, USA; Department of Neurology, Boston Children's Hospital, Boston, MA, USA.
Partners Multiple Sclerosis Center, Brigham and Women's Hospital, 1 Brookline Place, Boston, MA, USA.
Mult Scler Relat Disord. 2014 Mar;3(2):186-93. doi: 10.1016/j.msard.2013.06.004. Epub 2013 Jul 12.
To compare relapse rates in pediatric-onset multiple sclerosis (POMS) and adult-onset multiple sclerosis (AOMS) over the first 6-years of disease.
Patients with relapsing-remitting disease onset were identified from the Partners Pediatric MS Center, Massachusetts General Hospital and Partners MS Center, Brigham and Women's Hospital. 84 POMS and 258 AOMS patients were included. Annualized relapse rates (ARR) for each individual year from year 1 to year 6, after first attack were compared using Poisson regression, as was expanded disability status scale (EDSS) score at the visit closest to each year interval.
ARR was significantly higher in POMS compared to AOMS at individual years (except year 4), and was not significantly affected by adjustment for gender, race and proportion of time on treatment. Despite a 2.30 times higher relapse rate over 6-years, EDSS between groups did not differ. ARR in years 1-5 did not impact year 5 disability measured by EDSS in POMS.
Our findings demonstrate that higher ARR in POMS relative to AOMS is sustained over 6-years, suggesting a more inflammatory nature and potential disconnect between relapses and disability measured by EDSS early in POMS. This data may be useful when designing clinical trials for POMS.
比较儿童期起病的多发性硬化症(POMS)和成人期起病的多发性硬化症(AOMS)在疾病最初6年的复发率。
从马萨诸塞州总医院的 Partners 儿科MS中心以及布莱根妇女医院的 Partners MS中心识别出复发缓解型疾病起病的患者。纳入了84例POMS患者和258例AOMS患者。使用泊松回归比较首次发作后第1年至第6年每年的年化复发率(ARR),以及最接近每年间隔时就诊的扩展残疾状态量表(EDSS)评分。
POMS的ARR在各年份(第4年除外)显著高于AOMS,并且不受性别、种族和治疗时间比例调整的显著影响。尽管6年期间复发率高出2.30倍,但两组之间的EDSS没有差异。POMS中第1 - 5年的ARR对第5年用EDSS测量的残疾情况没有影响。
我们的研究结果表明,POMS相对于AOMS更高的ARR在6年期间持续存在,提示POMS早期具有更强的炎症性质,以及复发与用EDSS测量的残疾之间可能存在脱节。这些数据在设计POMS的临床试验时可能有用。